Lilly Company Profile

✉ Email this page to a colleague

LILLY has one hundred and five approved drugs.

There is one US patent protecting LILLY drugs.

There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-seven supplementary protection certificates in thirteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	KEFUROX IN PLASTIC CONTAINER	cefuroxime sodium	INJECTABLE;INTRAVENOUS	062590-001	Jan 10, 1986		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Lilly	GEMZAR	gemcitabine hydrochloride	INJECTABLE;INJECTION	020509-002	May 15, 1996		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Lilly	CYMBALTA	duloxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021427-002	Aug 3, 2004	AB	RX	Yes	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318-002	Jun 25, 2008	6,770,623	⤷ Sign Up
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-001	Feb 4, 2004	5,217,974*PED	⤷ Sign Up
Lilly	PROZAC WEEKLY	fluoxetine hydrochloride	CAPSULE, DELAYED REL PELLETS;ORAL	021235-001	Feb 26, 2001	RE39030	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	For Injection	2 g/vial	➤ Subscribe	2007-08-24
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2008-02-04
➤ Subscribe	For Injection	750 mg/vial	➤ Subscribe	2016-10-06
➤ Subscribe	Tablets	2.5 mg	➤ Subscribe	2008-10-14
➤ Subscribe	Delayed-release Capsules	20 mg, 30 mg and 60 mg	➤ Subscribe	2008-08-04
➤ Subscribe	Capsules	10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg	➤ Subscribe	2007-05-29
➤ Subscribe	Capsules	3 mg/25 mg	➤ Subscribe	2008-05-08
➤ Subscribe	For Injection	1g/vial	➤ Subscribe	2005-11-14
➤ Subscribe	For Injection	100 mg/vial	➤ Subscribe	2008-07-01
➤ Subscribe	For Injection	1000 mg/vial	➤ Subscribe	2012-06-27
➤ Subscribe	Injection	250 mcg/mL, 2.4 mL prefilled Pen	➤ Subscribe	2015-07-27
➤ Subscribe	Tablets	5 mg, 10 mg and 20 mg	➤ Subscribe	2007-11-21
➤ Subscribe	Delayed-release Capsules	40 mg	➤ Subscribe	2012-05-10
➤ Subscribe	Capsules	6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg	➤ Subscribe	2005-01-10
➤ Subscribe	For Injection	200 mg/vial	➤ Subscribe	2005-11-01

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	122014000088	Germany	⤷ Sign Up	PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT ATORVASTATIN ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE ATORVASTATIN ALS ATORVASTATINCALCIUMTRIHYDRAT; NAT. REGISTRATION NO/DATE: 90223.00.00 20141113; FIRST REGISTRATION: FRANKREICH CIS: 6 928 917 6 20140912
0113964	97C0037	Belgium	⤷ Sign Up	PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
1539166	92323	Luxembourg	⤷ Sign Up	PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.